$0.14 EPS Expected for Corcept Therapeutics (CORT); Amn Healthcare Services (AMN) Shorts Increased By 1.32%

October 13, 2017 - By Marie Mckinney

Analysts expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to report $0.14 EPS on November, 7.They anticipate $0.12 EPS change or 600.00% from last quarter’s $0.02 EPS. CORT’s profit would be $15.86M giving it 32.00 P/E if the $0.14 EPS is correct. After having $0.10 EPS previously, Corcept Therapeutics Incorporated’s analysts see 40.00% EPS growth. The stock decreased 4.07% or $0.76 during the last trading session, reaching $17.92. About 1.40 million shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 124.81% since October 13, 2016 and is uptrending. It has outperformed by 108.11% the S&P500.

Amn Healthcare Services Incorporated (NYSE:AMN) had an increase of 1.32% in short interest. AMN’s SI was 9.96 million shares in October as released by FINRA. Its up 1.32% from 9.83M shares previously. With 429,100 avg volume, 23 days are for Amn Healthcare Services Incorporated (NYSE:AMN)’s short sellers to cover AMN’s short positions. The SI to Amn Healthcare Services Incorporated’s float is 21.17%. The stock decreased 0.48% or $0.2 on October 13, reaching $41.4. About 423,658 shares traded. AMN Healthcare Services, Inc. (NYSE:AMN) has risen 7.60% since October 13, 2016 and is uptrending. It has underperformed by 9.10% the S&P500.

Since May 4, 2017, it had 1 buy, and 0 insider sales for $54,588 activity. Robb Gary Charles bought $54,588 worth of stock or 5,600 shares.

Investors sentiment increased to 2.43 in Q2 2017. Its up 1.35, from 1.08 in 2017Q1. It is positive, as 11 investors sold Corcept Therapeutics Incorporated shares while 29 reduced holdings. 36 funds opened positions while 61 raised stakes. 67.64 million shares or 12.48% more from 60.14 million shares in 2017Q1 were reported. First Quadrant Ltd Partnership Ca has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 2,806 shares. Intl Grp invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). The New York-based Amalgamated Bank has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). D E Shaw And Incorporated reported 0.01% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Investor Ab reported 0.62% stake. Mckinley Cap Ltd Company Delaware holds 445,517 shares or 0.2% of its portfolio. Jefferies holds 150,000 shares or 0.01% of its portfolio. 22,000 are held by Gabelli And Advisers. Moreover, California Public Employees Retirement Systems has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 148,200 shares. Suntrust Banks Inc has invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Bancorp Of Montreal Can owns 34,931 shares for 0% of their portfolio. Blair William And Com Il reported 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Peak6 L P, a Illinois-based fund reported 800 shares. 264,095 are held by Smith Asset Mngmt Grp L P. Essex Mgmt Company Ltd Limited Liability Company holds 0.64% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 378,846 shares.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 6 analyst reports since February 2, 2017 according to SRatingsIntel. Ladenburg Thalmann initiated the stock with “Buy” rating in Thursday, February 2 report. Piper Jaffray maintained it with “Buy” rating and $24.0 target in Wednesday, October 11 report. Piper Jaffray maintained it with “Buy” rating and $24.0 target in Friday, September 8 report. Piper Jaffray maintained the stock with “Buy” rating in Thursday, August 24 report.

Corcept Therapeutics Incorporated is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company has market cap of $2.03 billion. The Firm is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor . It has a 89.68 P/E ratio. As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor.

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services at acute and sub-acute care hospitals and other healthcare facilities throughout the United States. The company has market cap of $1.98 billion. The Company’s divisions include nurse and allied solutions, locum tenens solutions and other workforce solutions. It has a 17.5 P/E ratio. Through its suite of solutions, the Company provides technology, analytics and services to build and manage all or a portion of its clients’ healthcare workforce needs, from nurses, doctors and allied health professionals to healthcare leaders and executives.

Among 3 analysts covering AMN Healthcare (NYSE:AMN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. AMN Healthcare had 4 analyst reports since January 20, 2017 according to SRatingsIntel. The rating was downgraded by Avondale on Tuesday, January 24 to “Mkt Perform”. The stock of AMN Healthcare Services, Inc. (NYSE:AMN) earned “Buy” rating by Benchmark on Friday, January 20. The firm has “Outperform” rating given on Tuesday, June 27 by Wells Fargo. The stock of AMN Healthcare Services, Inc. (NYSE:AMN) earned “Buy” rating by Benchmark on Friday, February 17.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com